Respiratorius AB (publ) (XSAT:RESP)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.485
+0.020 (1.37%)
At close: Jan 14, 2026
-78.97%
Market Cap11.74M
Revenue (ttm)n/a
Net Income (ttm)-7.12M
Shares Out7.90M
EPS (ttm)-1.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume12,460
Average Volume11,075
Open1.455
Previous Close1.465
Day's Range1.455 - 1.540
52-Week Range1.455 - 10.500
Beta1.70
RSI35.10
Earnings DateFeb 10, 2026

About Respiratorius AB

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company’s products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 1
Stock Exchange Spotlight Stock Market
Ticker Symbol RESP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.